BIOMAT Database Logo BIOMAT Database Logo

Phase I study of recombinant carcinoembryonic antigen (CEA) vaccinia virus vaccine with post vaccination carcinoembryonic antigen peptide (CAP-1) boost. 2000

D J Cole, and P L Baron, and P O'Brien, and C E Reed, and J Schlom, and K Y Tsang
MUSC Department of Surgery and Hollings Cancer Center, Charleston, South Carolina 29425, USA. coledj@musc.edu

UI MeSH Term Description Entries

Related Publications

D J Cole, and P L Baron, and P O'Brien, and C E Reed, and J Schlom, and K Y Tsang
A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA).
July 1991, International journal of cancer,
D J Cole, and P L Baron, and P O'Brien, and C E Reed, and J Schlom, and K Y Tsang
Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses.
December 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
D J Cole, and P L Baron, and P O'Brien, and C E Reed, and J Schlom, and K Y Tsang
Human autoantibodies to carcinoembryonic antigen (CEA) induced by a vaccinia-CEA vaccine.
January 2000, Clinical cancer research : an official journal of the American Association for Cancer Research,
D J Cole, and P L Baron, and P O'Brien, and C E Reed, and J Schlom, and K Y Tsang
Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus.
February 1999, Cancer research,
D J Cole, and P L Baron, and P O'Brien, and C E Reed, and J Schlom, and K Y Tsang
A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen.
June 1999, Clinical cancer research : an official journal of the American Association for Cancer Research,
D J Cole, and P L Baron, and P O'Brien, and C E Reed, and J Schlom, and K Y Tsang
Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine.
July 1992, Journal of the National Cancer Institute,
D J Cole, and P L Baron, and P O'Brien, and C E Reed, and J Schlom, and K Y Tsang
A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma.
January 2013, Journal for immunotherapy of cancer,
D J Cole, and P L Baron, and P O'Brien, and C E Reed, and J Schlom, and K Y Tsang
Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine.
July 1995, Journal of the National Cancer Institute,
D J Cole, and P L Baron, and P O'Brien, and C E Reed, and J Schlom, and K Y Tsang
Enhanced immune responses and anti-tumor activity by baculovirus recombinant carcinoembryonic antigen (CEA) in mice primed with the recombinant vaccinia CEA.
November 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy,
D J Cole, and P L Baron, and P O'Brien, and C E Reed, and J Schlom, and K Y Tsang
Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer.
September 1996, Annals of surgical oncology,
Copied contents to your clipboard!